Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 20 hours agoScore70
Body · original
#ESMO26 🧬 Epsametostat (HH2853) | Phase II
🎯 Advanced epithelioid sarcoma
💊 Dual EZH1/2 inhibitor
👥 94 pts | 75 efficacy-evaluable
📈 ORR: 40% | DCR: 77.3%
⏳ mPFS: 13.1 mo | mDoR: 15.6 mo
🎯 mOS: Not reached
⚠️ G≥3 TRAEs: 39.4%
🚀 Primary endpoint met!
52 views · 1 like · 1 repost · 0 replies
Conference abstracts
1017Pmatched by Developmental therapeutics
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663matched by - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.orgSource: Nieves Martinez Lago MD PhD · x.com